Neurocrine Appoints Lilly Vet to Lead Technical Operations, Signals Biologics Push

Event summary

  • Andrew Ratz, Ph.D., formerly an executive at Eli Lilly, has been promoted to Chief Technical Operations Officer (CTOO) at Neurocrine Biosciences.
  • Ratz joined Neurocrine in January 2025 as Senior Vice President of Drug Development, Delivery and Device.
  • His previous role at Eli Lilly spanned 30 years, encompassing drug and device development, preclinical research through global manufacturing.
  • Ratz oversaw the development and registration of over 25 medicines across various therapeutic areas and drug modalities.

The big picture

Neurocrine's appointment of Ratz signals a deliberate move to diversify its therapeutic portfolio and capitalize on the growing biologics market. This represents a departure from their historical focus on small molecule drugs and reflects a broader trend among biopharma companies to pursue more complex and potentially higher-value therapies. The success of this transition will be vital for Neurocrine's long-term competitiveness and ability to address unmet medical needs.

What we're watching

Strategic Shift
Neurocrine's move to expand beyond small molecules into biologics and device-based therapies represents a significant strategic shift, and Ratz's experience will be critical to its success. The company's ability to integrate these new modalities into its existing portfolio will be a key indicator of its long-term growth potential.
Execution Risk
Ratz's track record at Eli Lilly is impressive, but transitioning a large-scale manufacturing and supply chain operation to a smaller biopharma company carries execution risk. Monitoring integration timelines and potential operational challenges will be crucial.
Pipeline Expansion
The success of Neurocrine's pipeline expansion into biologics will depend on Ratz's ability to build and manage a robust development and manufacturing infrastructure. The speed at which new biologic candidates advance through clinical trials will be a key performance indicator.